Compare Iris Energy Limited (IREN) vs Novavax Inc (NVAX) Price & Performance

IREN trades at $43.24, up 11.62% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 revenue of $501.02M and net income of $86.94M, but missed EPS estimates for three consecutive quarters. Recent news highlights a $2.8B AI contract surge and a raised revenue target above $4B, driving investor optimism despite high valuation ratios like a P/E of 51.6.

Outlook is mixed: strong AI contract growth and analyst consensus price target of $84.43 suggest upside, but execution risks, high valuations, and consistent earnings misses pose challenges. Stock sentiment is buoyed by institutional interest, including a new position by California State Teachers Retirement System in Q2 2026.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.